Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$5.97 +2.2%	$4.35	$3.21 ▼ $7.18	$1.44B	0.68	4.37 million shs	4.60 million shs
HROW Harrow	$38.82 -3.0%	$33.18	$20.85 ▼ $59.23	$1.44B	0.41	627,665 shs	879,943 shs
OLMA Olema Pharmaceuticals	$5.51 +4.8%	$4.64	$2.86 ▼ $13.93	$378.17M	1.92	530,869 shs	439,425 shs
VERA Vera Therapeutics	$21.54 +1.3%	$22.13	$18.53 ▼ $51.61	$1.37B	1.17	1.24 million shs	1.94 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	0.00%	+14.59%	+32.08%	+53.87%	+5.11%
HROW Harrow	0.00%	+12.75%	+7.42%	+36.64%	+4.78%
OLMA Olema Pharmaceuticals	0.00%	+18.75%	+22.17%	+16.99%	-54.16%
VERA Vera Therapeutics	0.00%	+8.84%	-9.34%	+1.36%	-43.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.3358 of 5 stars	3.5	2.0	4.4	3.4	2.5	0.6
HROW Harrow	2.8031 of 5 stars	3.5	1.0	0.0	3.8	2.5	0.6
OLMA Olema Pharmaceuticals	1.6321 of 5 stars	3.3	0.0	0.0	2.4	2.5	0.0
VERA Vera Therapeutics	3.5739 of 5 stars	4.5	3.0	0.0	1.6	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$11.50	92.63% Upside
HROW Harrow	3.00	Buy	$64.67	66.58% Upside
OLMA Olema Pharmaceuticals	2.67	Moderate Buy	$24.00	335.57% Upside
VERA Vera Therapeutics	2.90	Moderate Buy	$63.00	192.48% Upside

Current Analyst Ratings Breakdown

Latest OLMA, HROW, VERA, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $63.00
8/14/2025	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$28.00 ➝ $29.00
8/13/2025	HROW Harrow	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $64.00
8/12/2025	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $21.00
8/11/2025	OLMA Olema Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/7/2025	VERA Vera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$56.00 ➝ $53.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
8/5/2025	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00 ➝ $14.00
8/4/2025	VERA Vera Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$333.61M	4.31	N/A	N/A	$0.58 per share	10.29
HROW Harrow	$227.66M	6.31	$0.14 per share	283.90	$1.33 per share	29.19
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$5.03 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$7.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.23	N/A	19.26	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.25	N/A	97.05	N/A	-4.49%	-2.18%	-0.35%	N/A
OLMA Olema Pharmaceuticals	-$129.47M	-$1.98	N/A	N/A	N/A	N/A	-42.58%	-38.65%	N/A
VERA Vera Therapeutics	-$152.15M	-$3.58	N/A	N/A	N/A	N/A	-46.70%	-39.46%	N/A

Latest OLMA, HROW, VERA, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	HROW Harrow	$0.01	$0.24	+$0.23	$0.13	$64.23 million	$63.74 million
8/11/2025	Q2 2025	OLMA Olema Pharmaceuticals	-$0.43	-$0.51	-$0.08	-$0.51	N/A	N/A
8/5/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	-$1.20	-$0.38	-$1.20	N/A	N/A
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.44	4.30	4.03
HROW Harrow	0.78	0.62	0.85
OLMA Olema Pharmaceuticals	0.01	11.09	15.22
VERA Vera Therapeutics	0.16	17.03	17.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
HROW Harrow	72.76%
OLMA Olema Pharmaceuticals	91.78%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
HROW Harrow	15.16%
OLMA Olema Pharmaceuticals	16.36%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
HROW Harrow	180	37.00 million	31.39 million	Optionable
OLMA Olema Pharmaceuticals	70	68.63 million	57.41 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

OLMA, HROW, VERA, and ARDX Headlines

Recent News About These Companies

Deutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

August 15 at 3:42 AM | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.00 Average Price Target from Analysts

August 12, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Cuts Vera Therapeutics (NASDAQ:VERA) Price Target to $53.00

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA

August 10, 2025 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 10, 2025 | marketbeat.com

Lifesci Capital Issues Negative Forecast for VERA Earnings

August 10, 2025 | americanbankingnews.com

FY2025 EPS Estimates for VERA Cut by Cantor Fitzgerald

August 9, 2025 | marketbeat.com

HC Wainwright Has Negative Estimate for VERA Q3 Earnings

August 9, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for VERA Q3 Earnings?

August 9, 2025 | marketbeat.com

HC Wainwright Analysts Lower Earnings Estimates for VERA

August 9, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price

August 8, 2025 | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2025 | globenewswire.com

Vera Therapeutics Signs New Sales Agreement with TD Securities

August 8, 2025 | theglobeandmail.com

Q3 Earnings Forecast for Vera Therapeutics Issued By Wedbush

August 8, 2025 | marketbeat.com

Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.38 EPS

August 6, 2025 | marketbeat.com

Vera (VERA) Q2 Net Loss Widens 127%

August 6, 2025 | fool.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - What's Next?

August 5, 2025 | marketbeat.com

Wolfe Research Downgrades Vera Therapeutics (VERA)

August 5, 2025 | msn.com

Vera Therapeutics' (VERA) "Peer Perform" Rating Reaffirmed at Wolfe Research

August 5, 2025 | marketbeat.com

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OLMA, HROW, VERA, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

$5.97 +0.13 (+2.23%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$5.94 -0.02 (-0.42%)

As of 08/15/2025 08:00 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Harrow NASDAQ:HROW

$38.82 -1.19 (-2.97%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$39.08 +0.27 (+0.68%)

As of 08/15/2025 07:58 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Olema Pharmaceuticals NASDAQ:OLMA

$5.51 +0.25 (+4.75%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$5.38 -0.13 (-2.36%)

As of 08/15/2025 07:11 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Vera Therapeutics NASDAQ:VERA

$21.54 +0.27 (+1.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$21.82 +0.28 (+1.28%)

As of 08/15/2025 07:56 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time